David Marquino Cajiao, MS, MFT | |
2780 Sw 37th Ave, 206, Coconut Grove, FL 33133-2740 | |
(305) 496-8416 | |
Not Available |
Full Name | David Marquino Cajiao |
---|---|
Gender | Male |
Speciality | Marriage & Family Therapist |
Location | 2780 Sw 37th Ave, Coconut Grove, Florida |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1770974818 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
106H00000X | Marriage & Family Therapist | IMT1123 (Florida) | Primary |
Mailing Address | Practice Location Address |
---|---|
David Marquino Cajiao, MS, MFT 2780 Sw 37th Ave, 206, Coconut Grove, FL 33133-2740 Ph: (305) 496-8416 | David Marquino Cajiao, MS, MFT 2780 Sw 37th Ave, 206, Coconut Grove, FL 33133-2740 Ph: (305) 496-8416 |
News Archive
A new study led by researchers at the Beckman Institute for Advanced Science and Technology examined how cardiorespiratory fitness and body composition relate to neuronal health in 290 healthy young adults.
During Congress's August break, GOP lawmakers, armed with talking points, are maintaining strong positions against the overhaul and getting positive reinforcment from some of their constituents.
Vivakor, Inc. announces distribution of its VivaThermic products to the rapidly growing biotech/biopharma industries in India through its agreement with Pro Lab Marketing Pvt. Ltd.
If hospital doctors around the world often struggle to become those health centaurs, half professionals and half managers, that modern healthcare organizations need, the main responsibility is not their resistance to change, but the lack of effective support from the organization, according to a study by Marco Sartirana (CERGAS, Bocconi University), Graeme Currie (Warwick Business School), and Mirko Noordegraaf (Utrecht School of Governance), published by the Public Management Review.
CardioCell LLC has just received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with chronic heart failure (CHF), which generates more than 1 million hospitalizations annually.
› Verified 6 days ago